Introduction
CD16 (FcγRIII), a low-affinity receptor for the IgG Fc domain, facilitates antibody-dependent cell-mediated cytotoxicity (ADCC) and is responsible for triggering the lysis of target cells by natural killer (NK) cells. 1 Human NK cells comprise ~10% of all lymphocytes and are defined phenotypically by expression of CD56, absence of CD3, 2 and high density of CD16. 3 Human CD16 exists in two isoforms, CD16A and CD16B, that share 96% sequence identity in their immunoglobulin-binding regions. 4 CD16A is expressed on NK cells, macrophages, and mast cells and is an activating receptor. CD16B is expressed on granulocytes as a GPI-anchored receptor and does not trigger tumor cell killing. 4 ADCC is one of the major cytotoxic mechanisms employed by FcγR-expressing effector cells to eliminate tumor cells. Several immunotherapeutic approaches for oncology have explored the mobilization of ADCC-mediating effector cells, expressing FcγRs, by tumor antigen-specific IgGs. Thus, bispecific molecules binding to both tumor cells and either CD64 (FcγRI) or CD16 have been developed to improve effector cell recruitment. 5 Because NK cells mediate innate immunity and are constitutively activated, they are attractive candidates for cancer immunotherapy, and bispecific antibodies recruiting these cytotoxic cells (CD16/CD30 and CD16/HER-2) have been developed. 6, 7 Previously, there have been no reports of CD16A-specific antibodies lacking CD16B binding, and the majority of anti-CD16 antibodies bind both CD16 isoforms, CD16A and CD16B, except for two antibodies described as recognizing only CD16B. [8] [9] [10] CD16A-specific antibodies would engage NK cells without being removed from the circulation by CD16B + granulocytes, which represent up to 70% of leukocytes. Thus, an anti-CD16A antibody should allow the engineering of bi-or multi-specific molecules that target disease-associated cells via specific NK cell recruitment.
CD16A exhibits allelic polymorphisms at positions 48 and 158 of the Fc-binding domain. A previous report has demonstrated that IgG bind with different affinities to CD16A allotypes, due to polymorphism at position 158. 11 Since affinity to CD16A is implicated as important for the clinical efficacy of therapeutic antibodies, [12] [13] [14] and since the frequencies of these low/ high-affinity allotypes, 158F/V, are 0.6 and 0.4, 11 respectively, an anti-CD16A therapeutic antibody with similar affinity to both allelic forms, and hence potently activating NK cells in all patients, would be advantageous. Here, we report the incorporation of an anti-CD16A single chain antibody (scFv), which recognizes both CD16A allotypes with similar affinity and does not bind to CD16B, 15 into a tetravalent bispecific anti-CD30/anti-CD16A (CD30/CD16A) antibody format (TandAb®) comprising solely Fv domains 16 for the recruitment of NK cells to lyse CD30 + Hodgkin Reed-Sternberg (HRS) lymphoma cells. We describe the in vitro properties of this TandAb and compare its efficacy and mode of action to an anti-CD30 full-length IgG, with either native or enhanced Fc receptor binding properties, and a CD30/CD16A bispecific diabody.
Results

Selection of a specific anti-CD16A
To isolate a human antibody specific for CD16A, we screened a phage display library of scFv derived from human PBMCs and identified a CD16A-specific antibody that did not bind CD16B; after affinity maturation, we identified several mutants that bound CD16A with higher affinity than the original scFv with no loss of specificity (Table 1S) . Consistent with this specificity profile, affinity-matured scFvs demonstrated strong binding to CD16A + NK cells and no binding to CD16B + granulocytes. 15 The scFv most potently recruiting NK cells was selected using a cell cytotoxicity assay. We employed an IgG 1 antibody that binds the C-terminal scFv His-tags to promote pairwise binding to FcγRII + P-815 cells; 17 this emulates the bivalent binding of the bispecific TandAb, with anti-CD16A moieties, to effector NK cells. The relative amounts of cell lysis, induced by incubation of enriched human NK cells and calcein-labeled P-815 target cells in the presence of the scFvs, are shown in Figure 1A . With no crosslinking by anti-His IgG, lysis was similar to that of the negative controls (anti-CD3 IgG, anti-CD56 IgG, anti-CD3 scFv in the presence or absence of anti-His IgG). However dimerization of anti-CD16A scFvs, promoted by anti-His IgG, enhanced cytotoxicity toward P-815 cells. Thus, simultaneous crosslinking of FcγRII + target and NK effector cells, induced by the anti-His IgG-dimerized scFv, can trigger activating signaling and subsequent target cell lysis. The most efficacious anti-CD16A scFvs triggered cytotoxicity similar to that of control anti-CD16 and anti-NKp46 IgG. We thus selected the variable domains of LSIV21 (Fig. 1S) for TandAb incorporation.
Construction of a CD30/CD16A TandAb and diabody, and anti-CD30 IgGs
To compare the binding and cellular cytotoxicity of: (1) a tetravalent TandAb containing the anti-CD16A Fv described above, (2) a bivalent diabody, also containing this anti-CD16A Fv, and (3) an IgG, we utilized the Fv domains of the anti-CD30 antibody HRS-3. 6, 18 The gene organization and gene products for the TandAb and diabody are shown in Figure 1B -C. The characterization of the purified TandAb employing reducing and nonreducing SDS-PAGE and SE-HPLC revealed a purity of 96.2% homodimers (Fig. 2S) . The anti-CD30 IgG with a human IgG 1 is referred to as "the native IgG." The anti-CD30 IgG containing S239D/I332E Fc-mutations, which increase FcγR binding,19 is referred to as "the Fc-enhanced IgG."
Due to avidity, binding of a CD30/CD16A TandAb is enhanced relative to diabody and IgGs
We compared the affinities of the four constructs using a competitive binding assay employing CD30
+ KARPAS-299 target cells. A PE-labeled mAb (HRS-4), binding to the same epitope as HRS-3, from which the anti-CD30 Fv domains were derived, 20 served as the reference (Fig. 2A) . The IC 50 values, which were determined by nonlinear regression of the competition experiment between the PE-labeled anti-CD30 mAb, at constant concentration, and the four antibody constructs, added in increasing concentrations, were then used to calculate the K D values of the TandAb, diabody, and IgGs ( Table 1) . The affinities of all three antibodies that exhibited bivalent CD30-binding, the TandAb, the native and Fc-enhanced IgGs, were similar to each other, and more than an order of magnitude higher than that of the monovalent diabody ( Table 1) . Due to bivalent binding, 80% of the TandAb and IgGs are retained after 1 h at 37 °C compared with 10% of the monovalent diabody (Fig. 2B) . This suggests that the bivalent binding of the antibodies increases apparent affinity due to avidity.
To compare the CD16A and CD16B binding kinetics of the antibodies, we performed surface plasmon resonance (SPR) measurements with various allotypes of both CD16 isoforms fused to an Fc domain ( Table 2 ; Fig. 2C and D) . The apparent affinity of the TandAb to both allotypes of CD16A was 30-fold higher than that of the Fc-enhanced IgG, and more so compared with the diabody and the native IgG. While the CD16A k on rates of the antibodies were similar, the bivalent-binding TandAb exhibited k off that was substantially less than those of the monovalent-binding diabody and both IgGs (Table 2; Fig. 2C ). The bivalent TandAb exhibited no measurable binding to any CD16B allotype (Fig. 2D) , consistent with the original observations of the monovalent anti-CD16A scFv. 15 Furthermore, the TandAb displayed a sub-nanomolar apparent affinity to both CD16A allotypes, which was the highest among the assayed antibodies. The Fc-enhanced IgG and the diabody exhibited similar domains that are derived from the human scFv clone LSIV21 isolated from Affimed's phage display library. V H B and V L B stand for the murine anti-CD30 Fv domains that are derived from the HrS-3 IgG. The HrS-3 hybridoma-derived light chain contains two mutations in framework 1: tyrosine at L23, instead of the conserved cysteine that forms a disulfide bond with Cys L88 , and asparagine at L20, which is a potential glycosylation site. The residues at L20 and L23 were restored to the original amino acids in the germline sequence. The linker peptides (L) are of 9 amino acids length and consist of three Gly-Gly-Ser repeats.
affinities for CD16A, albeit their binding was 30-80-fold lower relative to that of the TandAb; in contrast, the CD16A binding of the native IgG was almost 1000-fold less than that of the TandAb. Both IgGs bound to CD16B, unlike the TandAb and the diabody. These data demonstrate that the TandAb possesses high apparent affinity to both CD16A allotypes and exquisite binding specificity manifested by exclusive binding to CD16A.
Cell surface retention assays on primary NK cells confirm the substantially slower dissociation of the bivalent TandAb relative to that of the monovalent diabody (Fig. 2E) . The fast dissociation of the diabody at 37 °C results in non-measureable FACS signals after a 5 min incubation of the cells in a large volume of medium, which prevents re-binding of dissociated antibodies. Therefore, the TandAb binding characteristics to both CD16A + NK cells and to CD16A in a cell-free SPR assay are consistent with its bivalent binding.
A CD30/CD16A TandAb exhibits superior cytotoxicity relative to diabody and IgGs
We established an in vitro cytotoxicity assay, employing calcein-labeled targets and enriched human NK effectors, to assess the biological activity of the TandAb, diabody and IgGs. The kinetics of a specific tumor cell line, KARPAS-299, lysis was monitored for 3 h at increasing antibody concentrations. For each antibody, sigmoidal dose-response curves were determined after 5, 15, 30, 60, 120, and 180 min incubation (Fig. 3S) , and used for the calculations of EC 50 and maximal cell lysis (Fig. 3A) . The TandAb and the diabody induced significant cytotoxicity of KARPAS-299 cells rapidly, in contrast to the native and Fc-enhanced IgGs. The maximal cell lysis induced by the TandAb and the diabody were similar, and always higher than that of IgG. However, the diabody EC 50 was 10-15 times higher than that of the TandAb at every time point, reflecting lower potency. The maximal cell lysis induced by the Fc-enhanced IgG peaked at less than half that of either the TandAb or the diabody.
To demonstrate that high affinity CD16A binding correlates with enhanced lytic potency and efficacy, we compared the residual cytotoxic activity of NK cells that were opsonized with three constructs and then permitted to dissociate (Fig. 3B) . Only NK cells incubated with the TandAb exhibited cytotoxic activity against KARPAS-299 tumor cells. This is in contrast to the observation where the antibodies were directly assayed with no subsequent dissociation step: each antibody exhibited the expected cytotoxic response. These assays demonstrate that the increased CD16A binding is critical to superior tumor cell cytotoxicity; such increased binding is due to higher avidity that reduces k off of the anti-CD16A domains, relative to the Fc domain of the IgGs. Moreover, cytotoxicity assays with KARPAS-299 tumor cells and phenotyped NK cells, presented in Figure 3C , demonstrated similar TandAb potency independent of CD16A NK cell allotype, which is consistent with possessing similar apparent TandAb affinity (158F homozygous: EC 50 17.0 pM, mean of n = 9; 158V homo-or heterozygous: EC 50 15.7 pM, mean of n = 6). The bispecific diabody exhibited cytotoxic potency, mediated by NK cells, that was independent of their CD16A allotype, as in the case of the TandAb. However, 
CD30/CD16A TandAb 948 pM, mean of n = 9; 158V homo-or heterozygous -EC 50 446 pM, mean of n = 4, and Fc-enhanced IgG: 158F homozygous: EC 50 256 pM, mean of n = 5; 158V homo-or heterozygous: EC 50 127 pM, mean of n = 2); a statistically significant difference (P = 0.017) was observed only for the native anti-CD30 IgG. Finally, we evaluated the cytotoxic activity of the TandAb against a panel of CD30 + cell lines derived from HL or anaplastic large-cell lymphoma tumors (Fig. 3D) . In all cases the TandAb elicited potent cytotoxicity, in the range of 3-40 pM, confirming its activity across a broad panel In the absence of CD30 + targets, CD30/CD16A TandAb elicits neither cytotoxicity nor NK cell activation
To determine whether bivalent CD16A-binding of the TandAb could result in systemic activation of NK cells and non-specific cell lysis, we first assayed cytokine release from human PBMC in the presence and absence of CD30 + KARPAS-299 cells. As a control, KARPAS-299 cells were cultured without human PBMC. Figure 4A shows tumor necrosis factor (TNF) and interferon (IFN)-γ release after incubation with increasing concentrations of TandAb for 24 h. The positive-control anti-CD3 antibody (OKT3), induced strong release of both cytokines, whereas the TandAb induced no or marginal cytokine production in PBMC cultures in the absence of CD30 + cells. When CD30 + cells were added to the cultures, at a PBMC-to-tumor cell ratio of 10:1, a dose-dependent secretion of TNF and IFN-γ was observed in the presence of the TandAb. The TandAb-induced cytokine release, however, was always less than that of OKT3. These data indicate that activation of NK cells is tightly linked to the presence of CD30 + tumor cells. Second, to further assess the specificity of NK cell activation by the TandAb, we performed a bystander cytotoxicity assay by co-culturing CD30 + and CD30 -target cells with NK cells at increasing concentrations of the TandAb. When calcein-labeled CD30 + /CD20 -KARPAS-299 cells were mixed with unlabeled CD30 -/CD20 + Raji cells, the TandAb induced dose-dependent lysis, while the rituximab control induced marginal lysis of KARPAS-299 (Fig. 4B) . In the inverse experiment, with calceinlabeled Raji and unlabeled KARPAS-299 cells, only rituximab mediated lysis of CD20 + Raji cells (Fig. 4C) . These data demonstrate that: (1) bivalent TandAb binding to NK cells does not trigger non-specific cytolytic activity, and (2) CD30 -bystander cells are not affected by TandAb-mediated target cell lysis. The lack of non-specific cytokine release and the absence of bystander cell killing, suggest that the TandAb should not mediate offtarget systemic NK cell activation that could lead to severe side effects. 21-23 CD30, which is highly expressed on HRS and anaplastic large cell lymphoma cells, but otherwise only on activated lymphocytes, has been implicated in the modulation of T cell activation and proliferation. 24 Encouraging results for the treatment of HL were obtained in two Phase 1 clinical studies using a bispecific quadroma antibody to recruit immune effector cells via CD16 binding. 25, 26 The quadroma was made by fusing two hybridomas: the first secreting an anti-CD30 antibody, and the second secreting an anti-CD16 antibody. The program was discontinued due to difficulties with production and purification of this bispecific quadroma antibody, although clinical results showed favorable activity. To overcome the manufacturing challenges, and to avoid potential cytokine release syndrome due to extensive cross-linking of immune effector cells via Fc domains, a bispecific diabody containing the Fv domains of the quadroma was developed. 6 It was efficacious at lysing tumor cells, but its low molecular weight (~50 kDa) precluded clinical development due to an unfavorable pharmacokinetic profile. Therefore, we developed an antibody that was twice as large as the diabody, employing a tetravalent bispecific antibody format (TandAb®), also comprised solely of antibody Fv domains. 16 TandAbs have two binding domains for each target molecule and a molecular Figure 2 (See previous page) . Binding weight of about 105-110 kDa, which is above the threshold for first-pass renal clearance.
Discussion
To optimize the clinical potential of TandAbs for recruiting NK cells, we screened a human antibody library for a specific anti-CD16A antibody. We isolated an affinity matured antibody with no binding to any CD16B allotype. The CD16A specificity of the TandAb may be advantageous because broad expression of the non-activating CD16B receptor on granulocytes may act as a sink for non-CD16A-specific antibodies, resulting in decreased efficacy. CD16A possesses two clinically-relevant allotypes, 158V and 158F, which bind immunoglobulins with higher and lower affinities, respectively. It was observed that trastuzumab-and rituximab-treated patients homozygous for the high affinity allotype, 158V/V, respond significantly better than patients who were heterozygous or homozygous for the low affinity allotype. [12] [13] [14] The anti-CD16A antibody described here similarly bound both CD16A allotypes, and it exhibited equivalent cytotoxic potency mediated by NK cells possessing either CD16A allotype. This suggests that the CD30/CD16A TandAb may benefit an expanded patient population. Bivalent CD16A-binding by the TandAb did not mediate offtarget NK cell activation in vitro; the TandAb only lysed cells expressing CD30. In the absence of target cells, there was no substantial release of cytokines, whether measured in the in vitro assay presented here, or during toxicological studies in cynomolgus monkeys, or in a Phase 1 clinical study (data not shown). Due to bivalent CD30 binding, both the TandAb and the corresponding IgGs exhibited similar apparent affinity to CD30 + target cells, which was more than 10-fold higher than that of the CD30-monovalent diabody. Moreover, due to much higher k off , molecules monovalently binding to CD16A (diabody, native, and Fc-enhanced IgGs) displayed lower affinity compared with that of the TandAb.
The higher avidity and the resultant lower k off of the TandAb for NK cells, leading to higher antibody retention, were apparent in the pre-opsonized effector cell cytotoxicity assay. Only NK cells incubated with the TandAb displayed cytotoxic activity. Furthermore, high amounts of the TandAb remained bound to NK cells in the presence of physiological concentrations of serum IgG. In contrast, even Fc-enhanced IgG exhibited substantially lower retention on, and binding at physiological concentrations of serum IgG to, NK cells, and this translated into substantially reduced cytotoxicity relative to the TandAb. This increased avidity of the TandAb may improve clinical efficacy in a broad HL patient population, and it could explain the demonstrated ability of the CD30/CD16A TandAb to overcome inhibition of HL-derived NK cells relative to those from healthy donors. 27 In cytotoxicity assays, the TandAb always performed better than the comparator constructs. The cytotoxic potency (EC 50 ) of the diabody and the Fc-enhanced IgG was 10-15-fold lower than that of the TandAb. Meanwhile, the cytotoxic efficacy (maximal cell lysis) of the Fc-enhanced IgG was more than 2-fold less than those of the similarly efficacious TandAb and diabody.
In conclusion, the significantly higher efficacy and potency of the TandAb relative to native and Fc-enhanced antibodies may result in better clinical response in the treatment of HL, and other cancers, through the improved targeted recruitment of immune effector cells.
Materials and Methods
Constructs
For constructing a TandAb, a diabody and an anti-CD30 IgG 1 , the Fv domains of the anti-CD30 IgG HRS-3 6,18 were modified as follows. Two substitutions, N20T and Y23C (Kabat numbering), were introduced into framework 1 of the V κ domain to remove a glycosylation site and to introduce a missing Cys residue by splice overlapping PCR, essentially as previously described. 28 In the TandAb and the diabody, the anti-CD30 domains were combined with the Fv domains of the affinitymatured anti-CD16A scFv clone LSIV21 that was isolated from a human phage display library as follows. 15 Anti-CD16A-specific scFv were isolated by phage display from a naïve IgM library comprising ~2 × 10 9 independent clones by three rounds of selection on biotinylated CD16A-Fc fusion protein. 29 After Figure 1S . In the diabody, the anti-CD16A domain was located as in the anti-CD16 domain of the previously described CD30/ CD16 diabody. 6 In the TandAb, the anti-CD30 and anti-CD16A domains were located identically as the anti-CD19 and anti-CD3 domains, respectively, of the previously described anti-CD19/anti-CD3 TandAb. 16 All three peptide linkers of the CD30/CD16A TandAb comprised nine amino acids, (Gly-GlySer) 3 . The Fc domain of the anti-CD30 antibody had human IgG 1 origin. An anti-CD30 IgG 1 with enhanced Fc-binding to CD16 was generated by introducing two Fc-mutations, S239D/I332E. 19 The eukaryotic expression plasmid for human CD16A-158V-Fc (pCDM8-CD16A 158V) was provided by Dr. Mandelboim. 29 The plasmid encoding the CD16A 158F-Fc fusion protein was obtained by mutating pCDM8-CD16A 158V. The plasmids encoding the ectodomains of the CD16B allotypes (NA1, NA2, and SH) fused to the Fc domain, were constructed from synthetic nucleotide sequences (Geneart), fused with the Fc domain, and cloned into the pSEC2 vector (Invitrogen, catalog number V900-20).
Expression and purification
The expression cassette for the TandAb was cloned into the mammalian expression vector pPBG-GPEX1, and the protein was produced (Rentschler) by perfusion fermentation in CHO cells. The TandAb secreted into the medium was harvested daily, stored at 4 °C, and the fractions collected over three weeks were pooled. After capture by hydrophobic charge induction chromatography, the product was purified by anion exchange and hydroxyapatite chromatography. The diabody was produced as previously described. 30 The anti-CD30 IgG expression vectors were generated by subcloning into pEU VH 1.2 and pEU VL 3.2 (Cambridge Antibody Technology Group Plc). IgG and Fc fusion proteins were secreted by transiently transfected HEK-293 cells and subsequently purified on Protein A.
CD16 affinity determination SPR analysis was performed (GE Healthcare, BIAcore X100, catalog number BR110073) on CD16-Fc fusion proteins that were either covalently coupled to (GE Healthcare, Amino Coupling Kit, catalog number BR100050) or directly immobilized on a CM5 chip (GE Healthcare, catalog number BR100399). The antibodies were diluted in 1x HBS-EP + buffer with 1 mg/mL NSB reducer (GE Healthcare, catalog number BR100691) to a concentration range of either 0.78-100 nM or 100-1600 nM depending on antibody affinity to CD16.
Biotinylation of antibodies
Biotinylation was performed according to manufacturer's instructions (GE Healthcare, Biotinylation Module, catalog number RPN2202). Free biotin was removed from the product (GE Healthcare, NAP5 column, catalog number 17-0853-01). The biotinylated product in individual column fractions was detected by dot blot analysis.
Cell culture and transient transfection HEK-293, Raji, P-815, KARPAS-299, L540CY, L428, L1236, and HDLM-2 cell lines were cultured under standard conditions in DMEM or RPMI 1640 medium supplemented with: 10% heat-inactivated FCS, 100 U/mL penicillin G, 100 µg/mL streptomycin, and 2 mM L-glutamine (all Invitrogen 33 and IC 50(I) is the concentration of the unlabeled competitor causing 50% inhibition of HRS-4 binding.
Cell surface retention assay
To quantify the retention of antibodies on CD30 + cells, aliquots of KARPAS-299 cells were incubated with 70 nM of biotinylated antibodies for 45 min on ice. After repeated washing with ice-cold FACS buffer, aliquots of 1 × 10 6 cells were suspended in 10 mL FACS buffer supplemented with 10% heat-inactivated FCS at 37 °C for the indicated time periods. After repeated washing, cell-retained antibodies were detected by DyLight™488-conjugated streptavidin (Dianova, catalog number 016-480-084) as described above. For enriched NK cells, the cell surface retention assay was performed as described for KARPAS-299, but the NK cells were stained with 1 µM CD30/CD16A TandAb or diabody for 45 min on ice, and after the 37 °C dissociation phase remaining cell-bound antibodies were labeled with anti-His IgG 13/45/31-2 (Dianova, catalog number Dia910) followed by FITC-conjugated goat anti-mouse IgG (Dianova, catalog number 115-095-062) and detected as described above. The mean fluorescence values at time-point 0 were taken to be 100%, and the remaining antibody was analyzed by nonlinear regression using GraphPad Prism.
Cytotoxicity assays Target cells were labeled with 10 µM calcein AM (Invitrogen, catalog number C3100MP) for 30 min in RPMI medium at 37°C, washed, and 1 × 10 4 cells were seeded together, with NK cells, in 200 µL at the indicated effector-to-target (E:T) ratios in the presence of increasing antibody concentrations. After incubation for the indicated time periods at 37 °C in a humidified 5% CO 2 atmosphere, the fluorescence (F) of calcein released into the supernatant was measured by plate reader at 520 nm F(spontaneous) represents fluorescence released from target cells in the absence of effector cells and antibodies, and F(maximum) represents that released after total cell lysis induced by addition of 1% Triton X 100 (Roth, catalog number 3051.2). Regression curves were fit to calculate EC 50 employing GraphPad Prism software. Statistical significance was assessed by a t test using GraphPad Prism software.
The redirected cytotoxicity assay with P-815 cells was performed as described above, employing the anti-CD16A scFv, 15 OKT3-derived scFv 6 , 34 anti-His antibody 13/45/31-2, OKT3 (Bioxcell, catalog number BE 0001-2), A9 20 provided by Dr. Moldenhauer (DKFZ Heidelberg), B159 (BD, catalog number 555514), and 195314 (R&D Systems, catalog number MAB1850).
Cytokine release assay Individual or mixed cultures of PBMC and KARPAS-299 were incubated in a 96-well micro-plate in the presence of the indicated antibodies for 24 h. Cytokines were quantified in the cell culture supernatant employing Procarta Cytokine Assay Kit, human 7-Plex Panomics, catalog number PC1007) and Luminex 100 Analyzer (Luminex, catalog number Lx100).
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